Report

Pulsatile MAPK Signaling Modulates p53 Activity to Control Cell Fate Decisions at the G2 Checkpoint for DNA Damage

Graphical Abstract

Highlights

- DNA damage elicits opposing pro-survival and pro-arrest responses via MAPK and p53
- MAPK pulsations modulate p53-dependent transcription to determine cell fate
- MAPK/p53 signal dynamics control the stringency of the G2 DNA damage checkpoint
- MAPK/p53 integrate extracellular and intracellular cues to protect genome integrity

Authors
Siddharth De, Callum Campbell, Ashok R. Venkitaraman, Alessandro Esposito

Correspondence
arv22@mrc-cu.cam.ac.uk (A.R.V.), ae275@mrc-cu.cam.ac.uk (A.E.)

In Brief
Cells coordinate repair and cell-cycle machinery in response to DNA damage to safeguard genomic integrity and tissue homeostasis. De et al. find that two opposing and pulsatile signals of pro-survival and pro-arrest networks permit cells to set a balance between distinct cell fates.

De et al., 2020, Cell Reports 30, 2083–2093
February 18, 2020 © 2020 The Author(s).
https://doi.org/10.1016/j.celrep.2020.01.074
Pulsatile MAPK Signaling Modulates p53 Activity to Control Cell Fate Decisions at the G2 Checkpoint for DNA Damage

Siddharth De,1,3 Callum Campbell,1 Ashok R. Venkitaraman,1,2,* and Alessandro Esposito1,2,4,*
1Medical Research Council Cancer Unit, University of Cambridge, Hills Road, Cambridge CB2 0XZ, UK
2Senior author
3Present address: Center for Chemical Biology & Therapeutics, Institute for Stem Cell Science & Regenerative Medicine (inStem), Bellary Road, Bangalore, India
4Lead Contact
*Correspondence: arv22@mrc-cu.cam.ac.uk (A.R.V.), ae275@mrc-cu.cam.ac.uk (A.E.)
https://doi.org/10.1016/j.celrep.2020.01.074

SUMMARY

Cell-autonomous changes in p53 expression govern the duration and outcome of cell-cycle arrest at the G2 checkpoint for DNA damage. Here, we report that mitogen-activated protein kinase (MAPK) signaling integrates extracellular cues with p53 dynamics to determine cell fate at the G2 checkpoint. Optogenetic tools and quantitative cell biochemistry reveal transient oscillations in MAPK activity dependent on ataxia-telangiectasia-mutated kinase after DNA damage. MAPK inhibition alters p53 dynamics and p53-dependent gene expression after checkpoint enforcement, prolonging G2 arrest. In contrast, sustained MAPK signaling induces the phosphorylation of CDC25C, and consequently, the accumulation of pro-mitotic kinases, thereby relaxing checkpoint stringency and permitting cells to evade prolonged G2 arrest and senescence induction. We propose a model in which this MAPK-mediated mechanism integrates extracellular cues with cell-autonomous p53-mediated signals, to safeguard genomic integrity during tissue proliferation. Early steps in oncogene-driven carcinogenesis may imbalance this tumor-suppressive mechanism to trigger genome instability.

INTRODUCTION

To maintain tissue function and homeostasis, mammalian cells respond to extracellular cues via signal transduction networks (STNs) that relay information from membrane receptors to the cell nucleus to influence cell fate decisions. The dynamic response of STNs (e.g., transient, oscillatory, or sustained) encodes fundamental information that controls cell fate (Purvis et al., 2012; Santos et al., 2007; Shankaran et al., 2009; Zwang et al., 2011), which is also recognized as a possible target for clinical modulation (Stewart-Ornstein and Lahav, 2017; Chen and Lahav, 2016).

Recent evidence suggests that cell fate decisions executed during processes that are seemingly cell autonomous may be regulated by STNs that respond to extracellular cues. One important example is the G2 cell-cycle checkpoint (Wei et al., 2010; Yan et al., 2007), which is activated by DNA lesions such as double-stranded DNA breaks (DSBs), and determines subsequent fates ranging from cell-cycle arrest to apoptosis (Shaltiel et al., 2015). Dynamic changes in the tumor suppressor p53 exemplify cell-autonomous mechanisms that control G2 checkpoint enforcement (Krenning et al., 2014; Batchelor et al., 2011; Loewer et al., 2010; Purvis et al., 2012). Pulses of p53 expression induced by DSBs mediate cell-cycle arrest, whereas sustained p53 activation instead triggers terminal cell fates, such as apoptosis or senescence (Batchelor et al., 2011; Purvis et al., 2012). These alternate fates are mediated through the differential transcriptional activation of downstream target genes that are dependent on the pattern (transient or periodic versus sustained) of upstream activators (Purvis et al., 2012; Loewer et al., 2010; Toettcher et al., 2009; Santos et al., 2007; Shankaran, 2009; Yamamoto et al., 2006). Emerging evidence (Yang et al., 2017) suggests that these processes may be influenced by extracellular cues such as growth-inducing signals, although the underlying mechanisms remain unclear. Such mechanisms are of central importance to understanding the complex response of multicellular tissues to DNA damage, which in turn underlies biological processes such as aging and carcinogenesis (Behrens et al., 2014; Ermolaeva et al., 2015). For instance, growing evidence implicates mitogen-activated protein kinase (MAPK) activation in the G2 checkpoint enforcement (Wang et al., 2007; Wei et al., 2010; Yan et al., 2007). MAPK signaling and its dynamics are known to control proliferation, influence the G1 DNA damage checkpoint (Santos et al., 2007; Zwang et al., 2011; Yamamoto et al., 2006; Tentner et al., 2012), and have a role at the G2 DNA damage checkpoint (Wei et al., 2010; Yan et al., 2007). However, it remains unclear mechanistically how MAPK dynamics exerts its influence, particularly in the G2 phase of the cell cycle and in the presence of DNA damage.

To address this issue, we have combined somatic cell genetics with optogenetics and single-cell biochemical imaging to investigate how the dynamic response of MAPK and p53 may intersect in determining cell fate during the G2 checkpoint. We reveal the previously unnoticed pulsatile activation of MAPK signaling after DNA damage and show how it intersects with the cell-autonomous control of p53 dynamics. We find that
sustained ERK activation, typical of early steps during oncogene-driven carcinogenesis, enhances the phosphorylation of CDC25C, promoting the accumulation of pro-mitotic factors such as CYCLIN B1 and PLK1. Increased PLK1 activity in turn relaxes the stringency of the G2 checkpoint, permitting cells to evade prolonged or irreversible cell-cycle arrest post-DNA damage. Our findings provide fresh insights into how the DNA damage checkpoint, a seemingly cell-autonomous mechanism, integrates information from the environment and thus plausibly sets a balance between safeguarding genomic integrity and maintaining tissue homeostasis.

RESULTS

MAPK Signaling Is Necessary for Recovery from the G2 Checkpoint

To investigate how MAPK exerts its influence over the DNA damage response, we used the human breast cancer cell line Michigan Cancer Foundation-7 (MCF-7), whose response to DNA damage has been extensively characterized (Batchelor et al., 2008, 2011). Initially, we tested whether MAPK signaling altered the G2 DNA damage checkpoint, as MAPK-dependent non-cell-autonomous mechanisms are poorly characterized in G2. Thus, we treated G2-synchronized MCF-7 cells (Figure S1A) with 200 ng/mL neocarzinostatin (NCS), a radiomimetic drug (Povirk, 1996; Smith et al., 1994) that primarily causes DSBs (Batchelor et al., 2011) with or without low concentrations of the well-characterized MEK inhibitor U0126 (U0126; Batchelor et al., 2011) or p53 (Purvis et al., 2012). This coordinated response of MAPK with p53 has not been reported previously, and it is evident also in RPE-1 cells (Figures S2A and S2B).

Damage-Induced MAPK Signaling Shapes p53-Dependent Transcriptional Programs

Mechanistically, p53 pulses maintain cells in an ambiguous state that enforces cell-cycle arrest and promotes DNA damage repair and cell survival by delaying cell death or senescence (Purvis et al., 2012). Therefore, we hypothesized that MAPK signaling may contribute to counteract p53-dependent mechanisms of cell-cycle arrest and withdrawal. While MEK inhibition alone has no effect on p53, in the presence of NCS-mediated DNA damage, U0126 further stabilizes p53, enhancing p53 expression in both MCF-7 and RPE-1 (Figures 1F, 1G, S2A, and S2B). The U0126-dependent stabilization may be caused by different levels of DNA damage or kinetics of repair in the presence or absence of U0126. Therefore, we measured the number of γH2AX foci per cell in MCF7 cells (a marker of DNA damage) by immunofluorescence at different times after exposure to NCS, again in the absence or presence of U0126 (Figures S1G and S1H). We observed no significant difference, suggesting that the stabilization of p53 observed is due to the regulation of the pathway by MAPK and not by the altered rate of DNA repair kinetics in the presence of the MAPK inhibitor.

Intermittent versus sustained activation of ERK (Aoki et al., 2013) or p53 (Purvis et al., 2012) upregulates the expression of distinct sets of genes, suggesting a possible MAPK-mediated mechanism of control of cell-cycle arrest. Thus, we analyzed the expression of transcripts encoding genes reported to be upregulated upon intermittent (downstream of ERK: c-FOS, EGR1, and DUSP1; downstream of p53: p21, GADD45a, and XPC) or sustained (ERK: JUN-B and CTGF; p53: BAX) ERK or p53 activation using quantitative real-time PCR analysis of messenger RNA (mRNA) up to 6 h after treatment with NCS (Figures S2D–S2G). Notably, the transient activation of ERK after DNA damage is sufficient to augment the transcript levels of genes reported to respond to pulsed activation such as EGR1, c-FOS, and CTGF, but it does not enhance to a detectable extent other targets such as DUSP1 and JUN-B or most of these genes (EGR1, CTGF, c-FOS, and JUN-B) in the presence of U0126 (Figures S2E and S2F). Similarly, we observe that the expression of those transcripts sensitive to p53 pulses (e.g., p21, GADD45a, XPC) are altered by the ablation of MAPK signaling, resulting in higher expression levels and altered kinetics (Figure S2G). At the same time, a gene such as BAX, which is insensitive to hour-long pulses of p53 (Purvis et al., 2012), remains unperturbed in the absence of MAPK signaling (Figure S2G). We also confirmed these observations on the transcriptional regulation of c-FOS.

DNA Damage Induces Oscillatory Activation of p53 and MAPK Signaling

To elucidate the mechanism of MAPK response, we quantified the MEK-dependent activating phosphorylation (pERK) of the extracellular signal-regulated kinases-1 and -2 (ERK) relative to total ERK (tERK), as surrogate measures of MAPK pathway activation. Irrespective of cell-cycle phase, ERK exhibits a peak of phosphorylation (pERK/tERK) at ~2 h, followed by a second peak 5 to 6 h later (i.e., 7~8 h after NCS treatment; Figures 1D and 1E) after treatment with 200 ng/mL NCS. The activation of ERK exhibits a dynamic very similar to that already reported for the dampened oscillations in p53 expression after DNA damage (Batchelor et al., 2008, 2011; Loewer et al., 2010; Purvis et al., 2012). This MEK1, 0.07 M, U0126 is specific for MEK2 and is sufficient to abrogate the MEK-mediated phosphorylation of ERK (Figure S1C). Live-cell imaging confirmed a DNA damage-induced arrest in G2, with only ~15% of cells progressing to mitosis within the duration of the experiment, compared to 40% in the absence of NCS (Figures 1A and 1B). The inhibition of MAPK signaling in the presence of DNA damage further decreases the fraction of cycling cells (<10%), together with longer mitotic timing. In the absence of NCS, U0126 alone did not alter the fraction of cycling cells or length of mitosis, confirming that the observed changes in checkpoint stringency are specific for the G2 DNA damage checkpoint and not non-specific effects on the G2/M transition or cells that may be in a different cell-cycle phase. We also obtained similar results using doxorubicin (a topoisomerase 2 inhibitor that causes DNA damage; Figure 1C) and the near-diploid non-transformed immortalized human retinal pigment epithelium (hTert-RPE) cells (Figures S1D–S1F), thereby confirming that the MAPK response and its effect on G2/M progression is specific to neither MCF-7 cells nor NCS.
and p21 with qPCR up to 10 h after DNA damage both in MCF-7 (Figure 1H) and RPE-1 (Figure S2C). These experiments thus demonstrate that a DNA damage-induced dynamic MAPK response does not solely alter p53 dynamics, but also significantly reshapes the dynamics and overall levels of both ERK and p53 downstream gene transcripts.

p53-Independent and ATM-Dependent ERK Phosphorylation

The similarities between the dynamic behavior of p53 expression and ERK activation after DNA damage prompted us to hypothesize that p53, which forms a natural oscillator with its partner MDM2 (Lahav, 2008; Lahav et al., 2004; Stewart-Ornstein and...
Lahav, 2017), triggers MAPK signaling. However, small interfering RNA (siRNA)-mediated depletion of p53 neither abrogated the activation nor changed the dynamics of MAPK signaling after DNA damage (Figures S3A–S3C), thereby indicating that p53 pulses are not responsible for the activation of ERK, but instead, upstream DNA damage checkpoint mediators could be acting independently to trigger p53 and ERK activation.

DSBs trigger the pulsatile activation of p53 via the checkpoint kinase ataxia telangiectasia mutated (ATM) (Batchelor et al., 2011). Therefore, we tested whether ATM was also necessary to activate the MAPK pathway after DNA damage. When NCS-treated MCF-7 was treated with 10 μM Ku55933, a well-characterized ATM-specific inhibitor (Hickson et al., 2004; Stagni et al., 2015; Lau et al., 2005; Mandriota et al., 2010), downstream targets of ATM such as CHK2 and p53 were not phosphorylated, resulting in the absence of p53 pulses (Figures S3D–S3F). ATM inhibition also led to a reduction in the activation of ERK, thereby confirming that DNA damage is responsible for the transient activation of ERK in an ATM-dependent manner (Figure S3E).

**ERK-Dependent Effects Are Mediated by Stochastic Pulses of ERK Activity**

To verify that the DNA damage-dependent oscillatory phosphorylation of ERK alters phenotypic outcomes in addition to its effect on p53 expression, we analyzed the phosphorylation of c-FOS at serine 374 (S374). Typically, c-FOS S374 is transiently phosphorylated by ERK, resulting in a partial stabilization that can be strengthened only when c-FOS is also phosphorylated at S324 upon sustained ERK activity (Murphy et al., 2002). We observed c-FOS stabilization and phosphorylation at S374 within the first hour after DNA damage, followed by a fast decrease to basal levels (Figure 2A). This result confirms that ERK pulsatile activation exhibits tangible effects at the transcriptional and post-translational levels that are known to be specific to transient (e.g., similar to an epidermal growth factor [EGF] response; Figures S4B and S4D) rather than sustained ERK activity (Aoki et al., 2013) (e.g., similar to a hereregulin [HRG] response; Figure S4C).

At single-cell resolution, ERK kinase activity either exhibits stochastic pulses in the absence of external stimuli (Aoki et al., 2013) or is activated in discrete pulses upon activation by growth factors such as EGF (Santos et al., 2007; Shankaran et al., 2009). To determine the nature of ERK activation at the single-cell level after DNA damage, we generated an MCF-7 cell line stably co-expressing the fluorescence resonance energy transfer (FRET)-based EKAREV biosensor and H2B-mCherry (MCF7-EKAREV; Figures 2B and S3G). This cell line reports on the ERK-dependent phosphorylation of the CDC25C-derived peptide around threonine 48. We validated this reporter cell line by monitoring responses to well-characterized mitogenic growth factors EGF (130 ng/mL) and HRG (100 ng/mL). As expected, EGF and HRG resulted in well-defined transient and sustained responses, respectively, both at a single-cell level (Figures S3H and S3I) and as population measurements (Figures S4A, S4C, and S4D). On the contrary, upon treatment with NCS, MCF7-EKAREV cells exhibited a prototypical stochastic activity of ERK (Aoki et al., 2013), which must be averaged over a population of cells (Figure 2C; n = 130 for NCS and n = 108 for control) to recapitulate observations on ERK phosphorylation from population ensembles. Thus, the phosphorylation of ERK and its subsequent increased activity, although seemingly stochastic at the single-cell level, results in a net increase in the phosphorylation of substrates such as c-FOS (Figure 2A), thereby speaking to the relevance of the pulsatile activation of the MAPK pathway post-DNA damage on its downstream targets.

**ERK Temporal Dynamics Dictates G2 Checkpoint Enforcement**

To provide further evidence supporting this notion, we modulated the temporal dynamics of ERK activity during G2 arrest by using EGF and HRG as tools. EGF and HRG are growth factors known to trigger transient (minutes long) or sustained (hours long) activation of ERK above basal levels, respectively (Cohen-Saidon et al., 2009; Nakakuki et al., 2010). Thus, we treated MCF-7 cells with either EGF at 130 ng/mL or HRG at 100 ng/mL, concentrations that were selected to obtain similar peak responses of ERK activity as measured by ERK phosphorylation in western blots (Figures S4C and S4D). EGF-induced transient ERK activation did not change the fraction of cells entering mitosis after the exposure of G2-synchronized cells to NCS (Figure S4E). In addition, transient stimulation with EGF at subsequent time points did not alter the timing or fidelity of the G2 DNA damage checkpoint (Figure S4F).

However, when G2-arrested MCF-7 cells were treated with HRG and NCS, we observed a 50% increase in cycling cells compared to NCS-treated cells alone (Figures 2D and 2E). Similar results were also obtained when cells were treated with doxorubicin (Figure 1C). We did not detect significant changes in the length of G2 in NCS- or HRG-treated cells (Figure S4H), indicating that a sustained mitogenic signal does not shorten the length of G2 arrest, but instead increases the likelihood that cells transit into mitosis. MCF-7 cells are defective in cell-cycle arrest when cells in the presence of DNA damage were treated with U0126, no changes for EGF pulses, and significantly fewer senescent cells with HRG with respect to the cells treated only with NCS (Figures 2F and S4I). We also tested whether modulation of MAPK signaling during the DNA damage response would result in differential survival in RPE-1 cells. RPE-1 cells were treated similarly to MCF-7 cells, but as RPE-1 cells can trigger apoptosis, we assessed their viability by CellTiter-Blue 3 days after treatment with NCS. Damaged cells showed higher viability when treated with HRG compared to cells treated with either EGF, U0126, or NCS alone (Figure 2G), confirming the importance of MAPK signaling dynamics in the determination of cell fate during the DNA damage response.

Furthermore, we confirmed that HRG but not EGF decreases p53 expression (Figures 2H, 2I, and S5A–S5D) through a similar mechanism involving the MDM2–MDMX axis (Gerarduzzi et al., 2016; data not shown), again suggesting that MAPK dynamics is crucial to establish a balance between cell-cycle arrest and progression in a p53-dependent manner. The p53 levels could
be rescued by treating the cells with U0126 in the presence of HRG and DNA damage (Figures S5E and S5F). Aiming to further test whether the dynamic cooperation between p53 and MAPK signaling contributes to the determination of G2/M progression during the DNA damage response, we attempted to rescue the stringency of the G2/M checkpoint by treating cells with Nutlin in the presence of HRG. Nutlin is a well-characterized MDM2 inhibitor (Purvis et al., 2012; Porter et al., 2016) that causes the stabilization of p53. To achieve stable expression of p53 during DNA damage, we used a Nutlin treatment strategy similar to the one established previously by Purvis et al. (2012). Figure 2J shows that Nutlin can rescue the G2/M checkpoint arrest in the presence of DNA damage and HRG (see also Figure S4J), confirming our previous conclusions. Hence, taken together, our results provide multiple lines of evidence for a model wherein dynamic changes in MAPK signaling regulate the cell fate after DNA damage.
Optogenetic Validation of MAPK-Dependent Cell Fate Decisions at the G2 Checkpoint

To directly determine whether MAPK activity regulates cell fate decisions at the G2 checkpoint, we engineered a stable cell line (MCF7-OptoRaf; Figure 3A) expressing a light-activatable C-RAF (Aoki et al., 2013) protein, the apical MAPK, capable of inducing specific ERK activation. After exposure to blue light, OptoRaf translocates to the plasma membrane, where it can interact and activate MEK and, consequently, ERK. After exposure to 20 min of blue light, MCF7-OptoRaf cells exhibit increased phosphorylation of ERK compared to both unlit MCF7-OptoRaf and (lit or unlit) MCF-7 cells. MCF7-OptoRaf cells thus permit us to activate MAPK signaling selectively (Figure 3B). Optogenetics-mediated sustained activation of MAPK signaling also results in a net decrease of p53 levels, similar to that observed by pharmacological intervention with HRG (Figure 3C). Sustained activation of RAF during live cell imaging resulted in a significant increase in cells progressing into mitosis in the presence of DNA damage compared to parental cells exposed to equal light intensities (Figures 3D and 3E). Therefore, this result confirms that sustained ERK activation is necessary and sufficient to alter G2/M checkpoint recovery and suggests that it acts independently of other pathways. These results provide a first demonstration that cell fate decisions following the G2 checkpoint for DNA profoundly depend on MAPK signaling and its dynamics.

Sustained MAPK Activity Promotes Mitotic Entry despite the Presence of DNA Damage

Since sustained MAPK activation suffices to decrease p53 levels (and rescued in the presence of MAPK inhibitor U0126) and increases the frequency of cells progressing into mitosis after DNA damage (Figures 3 and S5C–S5F), we hypothesized that sustained ERK activation via HRG, but not transient activation via EGF, may increase the expression of pro-mitotic proteins (e.g., CYCLIN B1, PLK1) and the ERK-dependent phosphorylation of pro-mitotic substrates (e.g., CDC25C). We used CDC25C phosphorylation (Wang et al., 2007) as a marker for MAPK activity in the progression to mitosis. We observed that CDC25C modification increases in HRG-treated cells (see Figures 4A and S6C for MCF-7 and RPE-1 cells, respectively), even in the presence of DNA damage, while no phosphorylation...
is observed after DNA damage alone. Moreover, CDC25C phosphorylation is decreased by U0126 treatment, confirming its dependence on MAPK (Figure S5H). Furthermore, consistent with our hypothesis, HRG increases the expression of the pro-mitotic factors PLK1 and CYCLIN B1, even in the presence of DNA damage in both asynchronous and G2-synchronized MCF-7 cells (Figures 4B–4F), and a similar increase in PLK1 levels is observed in synchronized RPE-1 cells (Figures S6A and S6B), whereas no increase is seen in the presence of EGF (Figure S5G). Together with the observed decrease in p53 levels induced by HRG, this confirms that sustained MAPK activation weakens the G2 checkpoint, thereby permitting cells to progress into mitosis with unresolved DNA damage, as reported previously (Liang et al., 2014) and confirmed in Figure 5A by γH2AX staining. Thus, our findings define an unnoticed mechanism wherein dynamic changes in MAPK activity maintain an optimal balance between pro-survival and pro-arrest signals during the DNA damage response. Sustained MAPK activity imbalances this mechanism, enfeebling damage surveillance via the G2 checkpoint.

Figure 4. Sustained MAPK Signaling Allows Cells to Enter Mitosis after Damage-Induced G2 Arrest
(A) Representative western blot showing that CDC25C phosphorylation at T48 in synchronized MCF-7 cells is decreased in response to DNA damage and is restored by HRG.
(B) Representative western blot showing the expression levels of PLK1 and CYCLIN B1 in asynchronous MCF-7 cells after DNA damage, in the absence or presence of HRG.
(C) Quantification of the western blot showing an HRG-dependent increase in PLK1, even in the presence of NCS.
(D) Quantification of the western blot showing an HRG-dependent increase in CYCLIN B1, even in the presence of NCS.
(E) Representative western blot showing the expression of PLK1 in G2-synchronized MCF-7 cells in control and NCS-treated cells and in NCS- and HRG-treated cells.
(F) Quantification of the western blot showing that HRG can restore PLK1 expressing in synchronous cells to levels similar to undamaged cells. All of the experiments represent at least 3 independent repeats.
See also Figures S5 and S6.
DISCUSSION

Cell fate choices at cell-cycle checkpoints are critical for the maintenance of tissue homeostasis and the genomic integrity of the cell. However, it is now apparent that in mammalian cells, DNA damage checkpoints in the G1 and G2 phases of the cell cycle are not infallible (Deckbar et al., 2011; Löbrich and Jeggo, 2007), but often permit cell-cycle progression in the presence of DNA damage. It is conceivable that the fidelity of DNA damage checkpoints has evolved to balance the requirements that minimize the probability of the emergence of genomic instability, and to maximize at the same time the homeostatic requirements for tissue maintenance.

In this work, we demonstrate that MAPK signaling is activated by the acute exposure of cells to DNA damage, triggering previously unnoticed pulses of ERK activity that are reminiscent of the pulsatile behavior of p53. We find that the transient nature of MAPK activation and p53 expression cooperate to control specific transcriptional programs, moderating the p53 response and permitting the continued accumulation of pro-mitotic factors such as PLK1 and CYCLIN-B1, even during checkpoint enforcement. These data exemplify that the dynamic interaction between MAPK and p53 signaling is indispensable to poise cells in an ambiguous state (Lahav, 2004); both MAPK and p53 are conducive to DNA damage repair, cell death, and senescence and to cell-cycle progression (Figure 5B). The abrogation of MAPK signaling enhances checkpoint stringency, whereas its sustained stimulation with HRG or light-inducible RAF increases checkpoint negligence. Mechanistically, sustained MAPK signaling during checkpoint activation results in the

Figure 5. Cells Enter Mitosis with Unresolved DNA Damage
(A) Cells stained against phosphorylated H2AX, a marker of DNA damage visible in any phase of the cell cycle, showing the presence of unresolved DNA damage in cells that have entered mitosis (marked by arrows). Accompanying bright-field images clearly show rounded mitotic cells in the field of view. There is little or no damage in mitotic cells, which have either been left untreated or treated with U0126 or HRG alone. Scale bar: 25 μm.
(B) Graphical representation of the positive and negative feedback first identified by Lahav et al. (2004), subsequently modeled with the addition of the WIP1 phosphatase role in Batchelor et al. (2011), where ERK activity discovered in this work is exemplified with the reported MAPK-MDM2 interaction (Gerarduzzi et al., 2016).
(C) A simple competitive model for the DNA damage checkpoint. The pulsatile response of p53 is known to maintain DNA-damaged cells in an arrested state conducive to DNA damage repair without permanent withdrawal from the cell cycle. The pulsatile activation of the MAPK/ERK pathway after DNA damage is necessary for the maintenance of this pro-survival state. The loss of MAPK/ERK activation leads to increased p53 activity and an increased probability of permanent cell-cycle arrest, while sustained MAPK/ERK activation leads to a greater probability of checkpoint recovery from DNA damage-induced arrest mediated by CDC25C phosphorylation.

2090 Cell Reports 30, 2083–2093, February 18, 2020
MAPK/ERK-mediated phosphorylation of CDK25C, leading to the accumulation of pro-mitotic factors such as CYCLIN B1 and PLK1. Notably, we did not detect significant changes in the length of G2 in NCS- and HRG-treated cells, indicating that a sustained mitogenic signal does not shorten G2, but instead increases the probability that cells progress to mitosis rather than undergo prolonged cell-cycle arrest and/or cell death. Together with previous reports that not only demonstrate that signaling dynamics mediate cell fate determination (Batchelor et al., 2011; Purvis et al., 2012; Aoki et al., 2013; Santos et al., 2007) but also their relevance as actionable drug targets (Chen and Lahav, 2016; Santos et al., 2007), our findings highlight the importance of investigating cellular decisions together with temporal changes in the underlying biochemical networks.

We find that both MCF-7 and RPE1 cells exhibit similar overall dynamics for p53 expression and ERK activation after DNA damage. We detect some differences that can plausibly be attributed to well-known variations in p53 dynamics after different genotoxic challenges (Geva-Zatorsky et al., 2006; Wu et al., 2017). Thus, our results are consistent with the notion that the concurrent activation of apparently opposing signals is an important emerging feature characterizing cell fate choices at cell-cycle checkpoints. Our results also suggest that the strength of these opposing signals and their dynamics may vary between cell types and type of damage to fine-tune the stringency of checkpoint enforcement in a context-dependent manner.

Our proposal that a competing-networks model dictates cell fate choices following damage-induced G2 checkpoint activation attracts interesting parallels (Figure 5C). For instance, such a competing-networks model has been invoked to explain the balance between exit from mitosis and death in mitosis (Topham et al., 2015), wherein the rate of CYCLIN B1 degradation appears to compete against activation of the pro-apoptotic machinery, deciding cell fate at the spindle assembly checkpoint. Similarly, cell fate at the G2 checkpoint depends on background PLK1 activation (Liang et al., 2014; Jaiswal et al., 2017), and the opposing activities of p53 and inhibitor-of-apoptosis proteins (IAPs) (Paek et al., 2016) to set a balance between cell death and survival.

Notably, our findings demonstrate that the MAPK-dependent mechanism activated by DNA damage remains sensitive to extracellular cues such as growth factors, enabling tissue homeostasis to balance optimally with the tumor-suppressive function of the G2 checkpoint. The importance of these observations is highlighted by the possibility that this mechanism could be hijacked by oncogenic activation of RAS or other mutations within the RAS-dependent signal transduction networks (e.g., in EGF receptor [EGFR] or RAF). By weakening the G2 checkpoint via sustained MAPK activation, oncogene-driven proliferation may increase genome instability to promote cellular transformation.

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **LEAD CONTACT AND MATERIALS AVAILABILITY**

**EXPERIMENTAL MODEL AND SUBJECT DETAILS**

- Human Cell lines

**METHOD DETAILS**

- Plasmids
- Western blotting
- RT-PCR analysis
- Immunofluorescence assays
- Live cell imaging and image analysis
- Chemicals
- siRNA-mediated protein knock-downs
- Beta gal Assay
- Cell-Titer Blue Assay

**QUANTIFICATION AND STATISTICAL ANALYSIS**

- Statistical analyses
- Western Blotting

**DATA AND CODE AVAILABILITY**

Supplemental Information can be found online at https://doi.org/10.1016/j.celrep.2020.01.074.

**ACKNOWLEDGMENTS**

S.D. was supported by a Department of Biotechnology (DBT), Government of India, and Medical Research Council (MRC) Joint Centre award (MR/N501876/1), C.J.C. was supported by a Cambridge Cancer Centre studentship (C48525/A16680), and A.E. was supported by MRC core awards, to A.R.V. (MC_UU_12022/1 and MC_UU_12022/8). We thank Maximillian Fries, Horng-Jing Liang, and Paul Russell for their initial assistance in this work, and Pablo Oriol Valls for help during the revision of the manuscript. We also thank Rob Mahen for the kind gift of the mCherry-H2B plasmid, Prof. Galith Lahav for providing MCF-7 cells stably expressing p53-Venus used during preliminary experiments, Prof. Michiyuki Matsuda and Dr. Aoki Kazuhiko for providing the EKAREV FRET sensor, and Dr. Jun-Ichi Miyazaki for providing the vector backbone used for the EKAREV sensor.

**AUTHOR CONTRIBUTIONS**

S.D. planned, executed, and analyzed all of the experiments. A.E. wrote the MATLAB script for the single-cell analysis and analyzed the data for the experiments requiring the use of the EKAREV FRET sensor. C.C. assisted in the MATLAB scripting and data analysis. A.R.V. and A.E. conceptualized the project and analyzed the data. S.D., A.E., and A.R.V. wrote the manuscript.

**DECLARATION OF INTERESTS**

The authors declare no competing interests.

Received: March 20, 2019
Revised: December 4, 2019
Accepted: January 22, 2020
Published: February 18, 2020

**REFERENCES**

Aoki, K., Kumagai, Y., Sakurai, A., Komatsu, N., Fujita, Y., Shionyu, C., and Matsuda, M. (2013). Stochastic ERK activation induced by noise and cell-to-cell propagation regulates cell density-dependent proliferation. Mol. Cell 52, 529–540.

Batchelor, E., Mock, C.S., Bhan, I., Loewer, A., and Lahav, G. (2008). Recurrent initiation: a mechanism for triggering p53 pulses in response to DNA damage. Mol. Cell 30, 277–289.
Batchelor, E., Loewer, A., Mock, C., and Lahav, G. (2011). Stimulus-dependent dynamics of p53 in single cells. Mol. Syst. Biol. 7, 486.

Behrens, A., van Deursen, J.M., Rudolph, K.L., and Schumacher, B. (2014). Impact of genomic damage and ageing on stem cell function. Nat. Cell Biol. 16, 201–207.

Chen, S.H., and Lahav, G. (2016). Two is better than one; toward a rational design of combinatorial therapy. Curr. Opin. Struct. Biol. 41, 145–150.

Cohen-Saidon, C., Cohen, A.A., Sigal, A., Liron, Y., and Alon, U. (2009). Dynamics and variability of ERK2 response to EGF in individual living cells. Mol. Cell 36, 885–893.

Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., et al. (2002). Mutations of the BRF1 gene in human cancer. Nature 417, 949–954.

Deckbar, D., Jeggo, P.A., and Löbrich, M. (2011). Understanding the limitations of radiation-induced cell cycle checkpoints. Crit. Rev. Biochem. Mol. Biol. 46, 271–283.

Ermolaeva, M.A., Dakkhinov, A., and Schumacher, B. (2015). Quality control mechanisms in cellular and systemic DNA damage responses. Ageing Res. Rev. 23 (Pt A), 3–11.

Favata, M.F., Horuchi, K.Y., Manos, E.J., Dauerlo, A.J., Stradley, D.A., Feeser, W.S., Van Dyk, D.E., Pitts, W.J., Earl, R.A., Hobbs, F., et al. (1996). Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 271, 18623–18632.

Gerarduzzi, C., de Polo, A., Liu, X.S., El Kharbili, M., Little, J.B., and Yuan, Z.M. (2016). Human epidermal growth factor receptor 4 (Her4) Suppresses p53 Protein via Targeting the MDMX-MDM2 Protein Complex: IMPlication OF A NOVEL MDMX SER-314 PHOSPHOSITE. J. Biol. Chem. 291, 25937–25949.

Geva-Zatorsky, N., Rosenfeld, N., Itzkovitz, S., Milo, R., Sigal, A., Dekel, E., Yarnitzky, T., Liron, Y., Polak, P., Lahav, G., and Alon, U. (2006). Oscillations and variability in the p53 system. Mol. Syst. Biol. 2, 2006.0033.

Hickson, I., Zhao, Y., Richardson, C.J., Green, S.J., Martin, N.M., Orr, A.I., Reaper, P.M., Jackson, S.P., Curtin, N.J., and Smith, G.C. (2004). Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 64, 9192–9195.

Jaiswal, H., Benada, F., Müller, E., Akopyan, K., Burdova, K., Koolmeister, T., Deckbar, D., Jeggo, P.A., and Löbrich, M. (2011). Understanding the limita-

Loewer, A., Batchelor, E., Gaglia, G., and Lahav, G. (2010). Basal dynamics of p53 reveal transcriptionally attenuated pulses in cycling cells. Cell 142, 89–100.

Mandriota, S.J., Buser, R., Lesne, L., Studier, C., Favaudon, V., Maechler, P., Béna, F., Clément, V., Ruegg, C., Montesano, R., and Sappino, A.P. (2010). Ataxia telangiectasia mutated (ATM) inhibition transforms human mammary gland epithelial cells. J. Biol. Chem. 285, 13092–13106.

Murphy, L.O., Smith, S., Chen, R.H., Fingar, D.C., and Blenis, J. (2002). Molecular interpretation of ERK signal duration by immediate early gene products. Nat. Cell Biol. 4, 556–564.

Nakakuki, T., Birnwistle, M.R., Saeke, Y., Yamoto, N., Ide, K., Nagashima, T., Bruschi, L., Oguminaie, B.A., Okada-Hatakeyama, M., and Khodolenko, B.N. (2010). Ligand-specific c-Fos expression emerges from the spatiotemporal control of Erk8 network dynamics. Cell 147, 884–896.

Niwa, H., Yamamura, K., and Miyazaki, J. (1991). Efficient selection for high-level expression of a eukaryotic protein in mammalian cells with a tetracycline-controlled expression vector. Gene 108, 193–199.

Paek, A.L., Liu, J.C., Loewer, A., Forrestor, W.W., and Lahav, G. (2016). Cell-to-Cell Variation in p53 Dynamics Leads to Fractional Killing. Cell 165, 631–642.

Porter, J.R., Fisher, B.E., and Batchelor, E. (2016). p53 Pulses Diversify Target Gene Expression Dynamics in an mRNA Half-Life-Dependent Manner and Delineate Co-regulated Target Gene Subnetworks. Cell Syst. 2, 272–282.

Povirk, L.F. (1996). DNA damage and mutagenesis by radiomimetic DNA-damaging agents: bleomycin, neocarzinostatin and other end nucleotides. Mutat. Res. 355, 71–89.

Putvis, J.E., Karhoths, K.W., Mock, C., Batchelor, E., Loewer, A., and Lahav, G. (2012). p53 dynamics control cell fate. Science 336, 1440–1444.

Santos, S.D., Verveer, P.J., and Bastiaens, P.I. (2007). Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate. Nat. Cell Biol. 9, 324–330.

Shaltiel, I.A., Krenning, L., Bruinsma, W., and Medema, R.H. (2015). The same, only different - DNA damage checkpoints and their reversal throughout the cell cycle. J. Cell Sci. 128, 607–620.

Shankaran, H., Ippolito, D.L., Chrisler, W.B., Resat, H., Bollinge, N., Opresko, L.K., and Wiley, H.S. (2009). Rapid and sustained nuclear-cytoplasmic ERK oscillations induced by epidermal growth factor. Mol. Syst. Biol. 5, 332.

Smith, B.L., Bauer, G.B., and Povirk, L.F. (1994). DNA damage induced by bleomycin, neocarzinostatin, and melphalan in a precisely positioned nucleosome. Asymmetry in protection at the periphery of nucleosome-bound DNA. J. Biol. Chem. 269, 30587–30594.

Stagni, V., Manni, I., Oropallo, V., Mottolese, M., Di Benedetto, A.P., Falcioni, R., Giaccari, D., Di Carlo, S., Sperati, F., et al. (2015). ATM kinase sustains HER2 tumorigenicity in breast cancer. Nat. Commun. 6, 6886.

Stewart-Ornstein, J., and Lahav, G. (2017). p53 dynamics in response to DNA damage vary across cell lines and are shaped by efficiency of DNA repair and activity of the kinase ATM. Sci. Signal. 10, eaah6671.

Tentner, A.R., Lee, M.J., Ostheimer, G.J., Samson, L.D., Lauffenburger, D.A., and Yaffe, M.B. (2012). Combined experimental and computational analysis of DNA damage signaling reveals context-dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress. Mol. Syst. Biol. 8, 566.

Toettcher, J.E., Loewer, A., Ostheimer, G.J., Yaffe, M.B., Tidor, B., and Lahav, G. (2009). Distinct mechanisms act in concert to mediate cell cycle arrest. Proc. Natl. Acad. Sci. USA 106, 785–790.

Topham, C., Tighe, A., Ly, P., Bennett, A., Sloss, O., Nelson, L., Ridgway, R.A., Hueis, D., Littler, S., Schandl, C., et al. (2015). MYC is a Major Determinant of Mitotic Cell Fate. Cancer Cell 28, 129–140.

Wang, R., He, G., Nelman-Gonzalez, M., Ashorn, C.L., Gallick, G.E., Stukenberg, P.T., Rinchik, M.W., and Kuang, J. (2007). Regulation of Cdc25C by ERK-MAP kinases during the G2/M transition. Cell 128, 1119–1132.

2092  Cell Reports 30, 2083–2093, February 18, 2020
Wei, F., Xie, Y., Tao, L., and Tang, D. (2010). Both ERK1 and ERK2 kinases promote G2/M arrest in etoposide-treated MCF7 cells by facilitating ATM activation. Cell. Signal. 22, 1783–1789.

Wu, M., Ye, H., Tang, Z., Shao, C., Lu, G., Chen, B., Yang, Y., Wang, G., and Hao, H. (2017). p53 dynamics orchestrates with binding affinity to target genes for cell fate decision. Cell Death Dis. 8, e3130.

Yamamoto, T., Ebisuya, M., Ashida, F., Okamoto, K., Yonehara, S., and Nishida, E. (2006). Continuous ERK activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression. Curr. Biol. 16, 1171–1182.

Yan, Y., Black, C.P., and Cowan, K.H. (2007). Irradiation-induced G2/M checkpoint response requires ERK1/2 activation. Oncogene 26, 4689–4698.

Yang, H.W., Chung, M., Kudo, T., and Meyer, T. (2017). Competing memories of mitogen and p53 signalling control cell-cycle entry. Nature 549, 404–408.

Zwang, Y., Sas-Chen, A., Drier, Y., Shay, T., Avraham, R., Lauriola, M., Shema, E., Lidor-Nili, E., Jacob-Hirsch, J., Amariglio, N., et al. (2011). Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. Mol. Cell 42, 524–535.
## STAR METHODS

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| p53 (DO-1)          | Santa Cruz | sc-126; RRID:AB_628082 |
| phospho-p44/42 MAPK (E10) | Cell Signaling | #9106; RRID:AB_331768 |
| p44/42 MAPK         | Cell Signaling | # 9102S; RRID:AB_330744 |
| Beta-actin          | Sigma-Aldrich | A2228; RRID:AB_476697 |
| ATM                 | Sigma-Aldrich | A1106; RRID:AB_796190 |
| phospho-ATM (Ser1981) [EP1890Y] | AbCam | ab81292; RRID:AB_1640207 |
| phospho-c-Fos (Ser374) | Calbiochem | NA |
| c-Fos               | Santa Cruz | sc-166940; RRID:AB_10609634 |
| phospho-cdc25C (Thr48) | Cell Signaling | #12028; RRID:AB_2797802 |
| Cdc25c (C20)        | Santa Cruz | sc-327; RRID:AB_2075277 |
| EGFP (JL-8)         | Clontech | 632380; RRID:AB_10013427 |
| c-Raf               | Cell Signaling | #9422; RRID:AB_390808 |
| Plk1                | Invitrogen | #33-1700; RRID:AB_2533104 |
| Cyclin B1           | Santa Cruz | sc-245; RRID:AB_627338 |
| phospho-MAPK substrates motif PXpTP | Cell Signaling | #14378; RRID:AB_2798468 |
| IR800 CW            | Li-Cor | 926-32210; RRID:AB_621842 |
| IR 680 RD           | Li-Cor | 926-68073; RRID:AB_10954442 |
| gH2AX antibody      | Calbiochem | 05-636; RRID:AB_309864 |
| **Bacterial and Virus Strains** |        |            |
| One Shot TOP10 Chemically Competent E. coli | Thermo Fisher Scientific (Life Technologies) | C404010 |
| **Chemicals, Peptides, and Recombinant Proteins** |        |            |
| InSolution-U0126    | Calbiochem | 662009 |
| recombinant HRG rhNRG1Beta/HRG1-Beta 1 | R&D systems | 396-HB |
| EGF                 | Sigma-Aldrich | E9644 |
| Ku-55933            | Selleck Chemicals | S1092 |
| Doxorubicin         | Sigma-Aldrich | D1515 |
| Neocarzinostatin    | Sigma-Aldrich | N9162-100UG |
| Lipofectamine 2000 Transfection Reagent | ThermoFisher | Cat# 11668019 |
| **Critical Commercial Assays** |        |            |
| First Strand cDNA Synthesis Kit for RT-PCR (AMV) | Roche | 04896866001 |
| LightCycler 480 SYBR Green Master Mix | Roche | 04707516001 |
| RNeasy mini kit     | QiAGEN | 74104 |
| Senescence β-Galactosidase Staining Kit | Cell Signaling | #9860 |
| **Experimental Models: Cell Lines** |        |            |
| MCF-7               | Cancer Research UK Cell Services | NA |
| hTERT-RPE 1         | ATCC | CRL-4000 |
| **Oligonucleotides** |        |            |
| RT-PCR primer: EGR1 FP: CTT CAA CCC TCA GGC GGA CA RP: GAA AAG CGG CCA GTA TAG GT | Sigma-Aldrich | NA |

(Continued on next page)
LEAD CONTACT AND MATERIALS AVAILABILITY

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Alessandro Esposito (ae275@mrc-cu.cam.ac.uk). All unique/stable reagents generated in this study are available from the Lead Contact without restriction.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

**Human Cell lines**

MCF-7 (Cancer Research UK Cell Services) and hTERT-RPE (ATCC, CRL-4000) cell lines were grown in standard DMEM and DMEM/F12, respectively, supplemented with 10% FCS. MCF-7 cell line stably expressing p53 fused with the Venus fluorescent protein (Purvis et al., 2012) was a gift from Prof. Galit Lahav and were used for the measurement of single cell G2 and M cell cycle traces. MCF-7 cells stably expressing the EKAREV sensor (MCF7-EKAREV) were derived from parental MCF-7 cells transfected with pEKAREV, then sorted into single cell (by single cell sorting) clones utilizing equal fluorescence emission of the donor and acceptor fluorophores, YPet and ECFP, to check for expression of a putatively intact sensor. MCF7-EKAREV transfected cells were validated by western blotting and imaging in the presence of EGF and HRG. MCF7-EKAREV cells were further modified to stably express

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| RT-PCR primer: JUN B FP | Sigma-Aldrich | NA |
| RT-PCR primer: FOS FP | Sigma-Aldrich | NA |
| RT-PCR primer: DUSP1 FP | Sigma-Aldrich | NA |
| RT-PCR primer: CTGF FP | Sigma-Aldrich | NA |
| RT-PCR primer: p21 FP | Sigma-Aldrich | NA |
| RT-PCR primer: GADD45a FP | Sigma-Aldrich | NA |
| RT-PCR primer: JUN B RP | Sigma-Aldrich | NA |
| RT-PCR primer: FOS RP | Sigma-Aldrich | NA |
| RT-PCR primer: DUSP1 RP | Sigma-Aldrich | NA |
| RT-PCR primer: CTGF RP | Sigma-Aldrich | NA |
| RT-PCR primer: p21 RP | Sigma-Aldrich | NA |
| RT-PCR primer: GADD45a RP | Sigma-Aldrich | NA |
| RT-PCR primer: GAPDH FP | Sigma-Aldrich | NA |
| RT-PCR primer: GAPDH RP | Sigma-Aldrich | NA |
| RT-PCR primer: XPC FP | Sigma-Aldrich | NA |
| RT-PCR primer: XPC RP | Sigma-Aldrich | NA |
| pEKAREV (3560NES) | Gift from Prof. Michiyuki Matsuda and Dr. Aoki Kazuhiro | Komatsu et al., 2011 |
| pCX4puro-CRY2-cRaf | Gift from Prof. Michiyuki Matsuda and Dr. Aoki Kazuhiro | Aoki et al., 2013 |
| pCX4neo-CIBN-EGFP-KRasCT | Gift from Prof. Michiyuki Matsuda and Dr. Aoki Kazuhiro | Aoki et al., 2013 |
| pcDNA3.1/nV5-DEST-mCherry-H2B | Gift from Dr. Rob Mahen | MRC-CU |

Software and Algorithms

| Software and Algorithms | Source | IDENTIFIER |
|-------------------------|--------|------------|
| GraphPad Prism 5 | GraphPad | [https://www.graphpad.com/scientific-software/prism/](https://www.graphpad.com/scientific-software/prism/) |
| Image Studio | LI-COR | [https://www.licor.com/bio/image-studio/](https://www.licor.com/bio/image-studio/) |
| MATLAB | Mathworks | [https://www.mathworks.com](https://www.mathworks.com) |
mCherry-H2B as nuclear marker, wherein cells with the integrated plasmid were selected utilizing single cell sorting to select the final clone that exhibited medium intensities for all the three fluorophores. The light-inducible CRY2-cRaf MCF-7 stable cell line (MCF7-OptoRaf) was derived from the MCF-7 parental line by retrovirally-mediated transduction of pCX4puro-CRY2-cRaf and pCX4neo-CiBN-EGFP-KRasCT followed by selection of a single clone using Puromycin and Neomycin selection. All cell lines were maintained at 37°C and 5% CO₂.

The identity of cell lines was confirmed by STR profiling utilizing the CRUK Cambridge Institute facilities. For cell cycle synchronization, cells were cultured in DMEM supplemented with 2mM thymidine for 16 hours. Cells were then washed 3 times with PBS and released in DMEM for 8 hours. A second identical thymidine block and release was subsequently applied typically obtaining > 50% MCF-7 in the S-phase once cells were released from the block and allowed to progress into the subsequent cell cycle phases. In average, cells were in G2 8 hr post-release; experiments were carried out at the time points indicated in the main text and figures. Mechanical stimulation or changes in the concentration of growth factors, such as the addition of fresh media, can activate MAPK signaling. Therefore, to avoid artifacts caused by the addition of drugs during the experiments, cells were grown for at least 12 hours in multwell or single plates (depending on the assay) to allow accomplishment of steady state activity of ERK signaling. Subsequently, small volumes of drugs or appropriate vehicle controls (0.8 μl into 2 ml) were added to the media that was already present in the wells (Figure S1B). The plates, which included also the controls, were then gently swirled by hand. This procedure provided us well-controlled and drug-specific responses in MAPK activity.

**METHOD DETAILS**

**Plasmids**

The plasmids encoding the FRET-based biosensor reporting for ERK activity (Komatsu et al., 2011) pEKAREV (3560NES) and the light-inducible RAF (Aoki et al., 2013) (pCX4puro-CRY2-cRaf and pCX4neo-CiBN-EGFP-KRasCT) were kindly provided by Prof. Michiyuki Matsuda and Dr. Aoki Kazuhiro. The pCX4 plasmids used to develop the optogenetic tools were provided by Dr. Jun-ichi Miyazaki (Niwa et al., 1991). The plasmid encoding for mCherry fused to histone H2B (pcDNA3.1/nV5-DEST-mCherry-H2B) was a gift by Dr. Rob Mahen.

**Western blotting**

Cells were lysed on the plate in RIPA buffer in the presence of protease and phosphatase Inhibitors; protein concentrations were estimated by BCA assay. The lysates were separated using 4%–12% NuPAGE Bis Tris SDS-PAGE gels (Invitrogen) and transferred to Amersham Protran nitrocellulose membrane (Catalogue number 10600008), followed by blocking with appropriate blocking buffer (5% milk or 5% BSA in Tris Buffered Saline-Tween). The membranes were incubated with the following primary antibodies in 5% milk blocking solution, unless otherwise indicated: mouse p53 (DO-1, Santa Cruz, 1:500), mouse phospho-p44/42 MAPK (Erk1/2, Thr202/Tyr204) (E10, Cell Signaling, 1:1000), rabbit phospho-cdc25C (Thr48) (Cell Signaling, 1:500), mouse ATM (Monoclonal, Sigma, 1:500), rabbit phospho-ATM (Ser1981) (AbCam,1:1000, Rabbit), mouse phospho-c-Fos (Thr202/Tyr204) (E10, Cell Signaling, 1:1000), mouse phospho-c-Fos (Thr202/Tyr204) (E10, Cell Signaling, 1:1000), mouse beta-actin (Sigma,1:10,000), mouse ATM (Monoclonal, Sigma, 1:500), rabbit phospho-ATM (Ser1981) (AbCam,1:1000, Rabbit), mouse phospho-c-Fos (Thr202/Tyr204) (E10, Cell Signaling, 1:1000), mouse Cyclin B1 (Santa Cruz, 1:1000), rabbit monoclonal phospho-MAPK substrates motif PXpTP (Cell Signaling 1:1000 in 5% BSA), mouse and rabbit antibodies were detected with anti-mouse (Cell Signaling, 1:1000), mouse Plk1 (Invitrogen, 1:1000), mouse Cyclin B1 (Santa Cruz, 1:1000), rabbit monoclonal phospho-MAPK substrates motif PXpTP (Cell Signaling 1:1000 in 5% BSA). Mouse and rabbit antibodies were detected with anti-mouse IR800 CW or anti-rabbit IR 680 RD (LI-COR antibody, 1:5000), respectively. Quantitative analysis of the western blots was achieved by imaging the membranes with the Odyssey scanner (LI-COR). All band intensities were analyzed using LI-COR Image Studio.

**RT-PCR analysis**

Cells were lysed and homogenized using the Qiashredder kit (QIAGEN, 79654), and RNA was isolated using the RNeasy mini kit (QIAGEN, 741104). 1 μg of RNA per sample was used to synthesize cDNA using the First Strand cDNA Synthesis Kit for RT-PCR (AMV) (Roche, 11483188001). The resulting 20μl cDNA samples were diluted to 50μl in RNase-free water. qRT-PCR was carried out in triplicates with LightCycler 480 SYBR Green Master Mix (Roche, 4707516001) using a LightCycler 480 instrument (Roche). Relative abundances were calculated as the ratio of 2^(-DCT) normalized to GAPDH. The following (forward and reverse)primer pairs were used for EGR1 (CTT CAA CCC TCA GGC GCA CA and GAA AAG CGG CCA GTA TAG GT), JUN B- (CTG GTG GCC TCT CTC TAC ACG and CCC GGC GGG GTA AAA GTA CTG), FO5 (AGG AGG AGG CTG ACT GAT ACA CT and TTT CCT TCT CCT TCA GCA GGT T), DUSP1 (TGT GGA GGA CAA CCA CAA GG and AAA CTC AAA GGC CTC GTC CA), CTGF (AGC CGC CTG TGC ATG GT and GGC AGT AGC GAT GCA CTT TT T G), p21 (TGA GCC GGC ACT GTG ATG and GTC TCG GTG ACA AAG TCG AAG TT), GADD45a (CGT TTT GCT GGC AGG AGC AC and GAA CCC ATT GAT CCA TGT AG), XPC (TGA GAC CAT ACC AGC CA and GGG CAT ACA GAG GGT GTT TC), and GAPDH (TGA GCT TGA CAA AGT GGT CG and GTC AGT GGT GGA CCT GAC CT).

**Immunofluorescence assays**

Cells were plated on coverslips in 6 well plates, subsequently synchronized by double-thymidine block, and released into fresh media. After 6 hours, cells were treated with NCS, U0126, EGF or HRG. At the same time, nocadazole (100 ng/ml) was added to prevent cells from completing mitosis. After 4 hours, cells were fixed with ice cold methanol for 15 minutes. DNA damage was then
probed with a γH2AX antibody (mouse, 1:1000, Calbiochem) and Goat ant-mouse Alexa Fluor 488 secondary antibody (1:500, Invitrogen). Images were acquired with a Leica SP5 confocal microscope, utilizing a HCXPLAPOCS 40x oil-immersion objective and analyzed with the Cellomics software.

**Live cell imaging and image analysis**

Cells were plated on 2- or 4-well Lab-Tek chambers (Thermo Fisher Scientific, Cat. No. 155380 2-wells and 155383 4-wells) washed and kept in DMEM without phenol red (Invitrogen, Cat. No. 31053028) supplemented with 10% FCS. Images were acquired with a motorized Leica DMi6000B microscope, using a HCX PL APO 40X/0.85 dry objective equipped with a fast switching filter-wheel dedicated to sensitized FRET imaging and a Photometrics Evolve 512 EMCCD camera. The same system was used to measure brightfield images. Each image was captured after every 3 minutes, with a minimum of 7 fields of view for each condition. Treatments were performed on stage after the setup of the imaging session, just prior to the start of imaging. For assays with synchronized cells, imaging started 6 hours after release from thymidine block with treatments as indicated in the main text and figures. According to flow cytometry (Figure S1A), this timing ensured that cells were tracked with live cell imaging starting from late S-phase or early G2-phase. Only cells that entered the first mitosis post-treatment were considered for analysis to avoid including cells that might have passed through multiple stages of the cell cycle. Moreover, only cells that entered mitosis within a maximum of 24 or 12 hr were considered for analysis to avoid spurious results from those cells that might be released late from G1. 24 hr was used for experiments with NCS and U0126, shortened to 12 hr for HRG and OptoRAF to account for possible agonists of MAPK signaling on G1/S transition.

The EKAREV FRET sensor was excited with a mercury short arc lamp using a 463 ± 20 nm band-pass filter. Fluorescence was separated with a dichroic mirror (455 nm cut-off wavelength) and fluorescence emitted from the ECFP and YPet were collected sequentially using the fast switching filter-wheel equipped with 480 ± 40 nm and 535 ± 30 nm band-pass filters, respectively. The ratio of fluorescence intensities emitted from YPet and ECFP (YPet/ECFP) was used as a surrogate measure of ERK activity (Komatsu et al., 2011). mCherry-H2B fluorescence was acquired with the standard N3/red filter from Leica. Typical acquisition times were around 120ms, 120ms and 300ms for YPET, ECFP and mCherry, respectively. Data analysis was performed with an in-house dedicated MATLAB toolbox (Mathworks) similar to what we have previously described (Liang et al., 2014). Briefly, data was imported in MATLAB with the Bio-Formats toolbox developed by the Open Microscopy Environment network and a gentle median filtering developed MATLAB toolbox (Mathworks) similar to what we have previously described (Liang et al., 2014). Data analysis was performed with an in-house dedicated MATLAB toolbox (Mathworks) similar to what we have previously described (Liang et al., 2014).

The EKAREV FRET sensor was excited with a mercury short arc lamp using a 463 ± 20 nm band-pass filter. Fluorescence was separated with a dichroic mirror (455 nm cut-off wavelength) and fluorescence emitted from the ECFP and YPet were collected sequentially using the fast switching filter-wheel equipped with 480 ± 40 nm and 535 ± 30 nm band-pass filters, respectively. The ratio of fluorescence intensities emitted from YPet and ECFP (YPet/ECFP) was used as a surrogate measure of ERK activity (Komatsu et al., 2011). mCherry-H2B fluorescence was acquired with the standard N3/red filter from Leica. Typical acquisition times were around 120ms, 120ms and 300ms for YPET, ECFP and mCherry, respectively. Data analysis was performed with an in-house dedicated MATLAB toolbox (Mathworks) similar to what we have previously described (Liang et al., 2014).

**Chemicals**

The MEK inhibitor InSolution-U0126 (662009, Calbiochem), recombinant HRG rhNRG1Beta/HRG1-Beta 1 (396-HB, R&D systems), EGF (Sigma), the ATM inhibitor Ku-55933 (S1092, Selleck Chemicals), Doxorubicin (Sigma, D1515) and the radiomimetic drug Neocarzinostatin (N9162-100UG, Sigma) were added to full media at the concentration described in the main text.

**siRNA-mediated protein knock-downs**

Cells were plated in 6 well multi-plates in standard DMEM supplemented with 10% FCS; the following day, cells were transfected with either 20mM of pooled siRNA targeting p53 (ON-TARGET plus Human TP53 (7157) siRNA, Thermo Scientific) or a control siRNA against Luciferase (MWG) using Lipofectamine 2000, following manufacturer’s protocol. 48 hours post-transfection, cells were treated at the desired time points with NCS as indicated in the main text, and then harvested for subsequent western blot analysis.

**Beta gal Assay**

After double-thymidine block, cells were plated in 6 multi-well plates in DMEM supplemented with 10% FCS. G2-synchronized cells were then treated with NCS, U0126, EGF and HRG: EGF single pulse at 1 hr, multiple EGF pulses at 1 and 3 hours, U0126 pre-treatment for 30 minutes before NCS addition and HRG at the time of NCS addition. Cells were then washed with fresh media after...
12 hours. Cells were fixed and stained after four days as per manufacturer protocol (Senescence \( \beta \)-Galactosidase Staining Kit #9860, Cell Signaling), and scored manually on a standard wide field microscope.

**Cell-Titer Blue Assay**

RPE-1 cells were plated in 96-well plate at a density of 2000 cells/well and synchronized with a single-thymidine block. 6 hours after release in fresh media, cells were treated with or without DNA damage, and HRG, EGF and U0126, in triplicates. After 3 days, cells were incubated with 20 \( \mu \)L of Cell-Titer Blue reagent (Promega, catalog number G8080) for 4 hours and the fluorescent values were measured at 560/590nm using Tecan Infinite m200 plate reader.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

**Statistical analyses**

All the reported multiple comparisons were performed as one-way ANOVA with Newman-Keuls multiple comparison test. Symbols to indicate statistical significance within figures related to \( p \) values thresholds of 0.05 (*), 0.01 (**) and 0.001 (***) as evaluated by GraphPad for post-test pairwise comparisons. For ANOVA tests, the exact \( p \) values on testing if all the means come from the same distribution are shown in Table S1. Here, also the \( p \) value for a two-tail-test used in Figure 4B is shown.

**Western Blotting**

Quantitative analysis of the western blots was achieved by imaging the membranes with the Odyssey scanner (LI-COR). All band intensities were analyzed using LI-COR Image Studio.

**DATA AND CODE AVAILABILITY**

The published article includes all datasets analyzed during this study. The code used to generate Figure 2C is provided in Data S1.
Supplemental Information

Pulsatile MAPK Signaling Modulates p53 Activity to Control Cell Fate Decisions at the G2 Checkpoint for DNA Damage

Siddharth De, Callum Campbell, Ashok R. Venkitaraman, and Alessandro Esposito
Figure S1. Validation of cell cycle synchronisation along with measurement of DNA damage in the absence or presence of U0126. DNA damage triggers p53 and MAPK oscillations that control checkpoint enforcement. Related to Figure 1.
Cell-cycle analysis of MCF-7 cells done by flow cytometry, showing that at 8 hrs after the second release from Thymidine block, a large fraction of cells (41%) are in G2/M compared to asynchronous cells (15%), fraction further increasing to ~50% at subsequent timepoints.

Representative Western Blot (n=2) of NCS treatment compared to a mock control (0.1% DMSO) showing that the pERK/ERK ratio and p53 expression do not change for unspecific chemical or mechanical stimuli that might occur during the addition of drugs to cell culture dishes. All the samples were run on the same gel, but the image was cropped to remove lysates from an unrelated experiment.

Representative Western Blot (n=2) of MEK inhibitor U0126 titration (0.05 µM, 0.25 µM, 0.5 µM and 1 µM) in the presence of NCS.

Cell fate traces of RPE cells either untreated or treated with 20 ng/ml (NCS), in the presence or absence of U0126 from one representative experiment of three repeats. In the presence of NCS, RPE cells exhibit a G2 arrest that is exacerbated by U0126, similarly to MCF-7 cells.

Quantification of the single cell fate traces of RPE cells from (c) shows a significant decrease in cells entering mitosis when treated with NCS (20 ng) which gets further exacerbated when cells are treated with both NCS and U0126 (n=3).

Quantification of number of synchronised RPE-1 cells entering mitosis when treated with Doxorubicin, along with U0126 and HRG. A significantly larger number of cells entered mitosis when cells were treated with HRG in the presence of Doxorubicin, while number of cells entering mitosis when treated with U0126 was significantly lower, indicating the enfeeblement of the G2 checkpoint (in the case of HRG) and higher stringency (in the case of U0126), upon the respective treatments (n=3).

Quantification of DNA damage and repair, as measured by number of gammaH2AX staining, in MCF7 cells when treated with NCS and in the absence or presence of U0126. No significant difference in gammaH2AX staining is observed between cells treated with NCS alone or treated with both NCS and U0126 (n=3).

Representative images from which the analysis shown in (c) was derived. Inset show a 2x magnification. Scale bar: 25µm
Figure S2. DNA-damage induced MAPK signalling reshapes cell transcriptional profiles. Related to Figure 1.

(A) Representative Western Blot of three independent experiments for p53 and pERK dynamics in RPE cells treated with NCS (20 ng/ml).

(B) Averages of p53 expression levels and pERK levels in RPE-1 cells post treatment with NCS. p53 expressions show a typical dynamic behaviour with two peaks with higher p53 expression levels when cells were treated with NCS and U0126. pERK/pERK levels also show a dynamic behaviour with peaks at approximately 2 hrs and 8 hrs, similar to those seen in MCF-7 cells (n=3)
(C) Expression profile of ERK target genes (c-FOS) and p53 target gene (p21) in RPE-1 cells when treated with NCS and with the concomitant inhibition of MAPK pathway inhibitor U0126 (n=3).

(D) Validation of ERK targets. qRT-PCR analysis (averages, n=3) of serum starved MCF7 cells treated with 100 ng/ml of EGF; this analysis confirms the transient response of ERK targets to EGF.

(E) Expression profile (mean± SEM) of ERK target genes (FOS, EGR1, CTGF, DUSP1, and JUN B) in the presence of DNA damage (n=3). Upon DNA damage, FOS, EGR1 and CTGF transcripts are upregulated, at least transiently.

(F) With the concomitant inhibition of MAPK signaling using U0126, DNA-damage fails to trigger the response of these transcripts (n=3). Cells treated only with U0126 at 0 hrs were used to determine transcript levels after MAPK inhibition.

(G) Expression profile (n=3) of p53 target genes (p21, GADD45a, XPC and BAX) in the presence of DNA damage without (red curves) and with U0126 (yellow curves). Similarly to ERK, some p53 targets are insensitive to U0126 administration, but others such as p21, known to respond to pulsatile p53 responses, are significantly upregulated by addition of U0126 in the presence of DNA damage.
Figure S3. DNA damage triggers p53 and MAPK oscillations that control checkpoint enforcement.
Related to Figures 2.

(A) Representative Western Blot (n=2) of p53 expression and ERK phosphorylation in the presence of DNA damage after p53 depletion revealing that silencing of p53 does not alter ERK expression and phosphorylation.
(B) Analysis of ERK phosphorylation shows that p53 depletion does not affect the phosphorylation dynamics of ERK after DNA damage.
(C) Expression levels of p53 post siRNA mediated depletion in the presence of DNA damage.
(D) Expression of ERK and DNA damage response proteins ATM, CHK2 and p53 after DNA damage in the presence or absence of Ku-55933.

(E) Analysis of ERK phosphorylation and,

(F) p53 expression (F) shows that ATM inhibition (ATMi) with Ku-55933 results in the abrogation of p53 response and a significant attenuation of ERK phosphorylation (n=2).

(G) Fluorescence images of the stable MCF7-EKAREV cell lines expressing a FRET-based ERK activity reporter and a nuclear marker (mCherry-H2B) scale bar: 50 µm.

(H) Bootstrapped analysis of MCF7-EKAREV cells, serum starved, and treated with 130 ng/ml EGF.

(I) Bootstrapped analysis of MCF7-EKAREV cells, serum starved, and treated with 100 ng/ml HRG.

(J) Single cell traces used to compute the bootstrapped distributions shown in Fig 2C.

(K) Bootstrapped average and 95% confidence interval for the FRET ratios shown in Fig. 2 presented without normalization to control average. Normalization was necessary to detrend curves as we detect a decrease of apparent FRET during the first two hours of measurements.
Figure S4. Validation of the MCF7-EKAREV cell line and growth factor treatments. Related to Figure 2.

(A) Western blot analysis of MCF7-EKAREV cells treated with 100 ng/ml EGF for 5 and 15 minutes. The sensor was immunoprecipitated with a GFP antibody and the phosphorylation of the CDC25C T48 motif used in the sensor was confirmed by probing with anti-PXpTP antibody, which recognises phosphorylation only in the context of a phosphorylated Threonine followed by a Proline.

(B) c-FOS phosphorylation after DNA damage and in the presence of EGF (HRG response showed in Fig. 2, n=2). Arrows indicate c-FOS phosphorylated at Ser374.

(C) Response of MCF7 cells to 100 ng/ml HRG induces sustained phosphorylation of ERK for several hours.

(D) MCF7 cells treated with 130 ng/ml EGFR exhibit a more transient response compared to HRG.
(E) Quantification of number of cells entering mitosis when treated with NCS and EGF shows no significant change between the two treatments thereby exhibiting that transient stimulation of MAPK pathway is not sufficient for allowing cells to move into mitosis in the presence of DNA damage (n=3).

(F) Pulses of MAPK activation induced by EGF treatment at different times do not change the fraction of cells released from G2 arrest (n=3).

(G) The transient nature of EGF response permitted us to use EGF to impose distinct pulses of MAPK activity with 130 ng/ml EGF for 15 minutes at the beginning of the experiments or after 105 minutes. Panel (G) shows two pulses separated by approximately two hours. Experiments were carried out in complete medium and cells were washed three times with complete medium 15 minutes after every EGF treatments.

(H) Quantification of time spent by MCF7 cells in G2 when treated with NCS and HRG shows no significant delay when compared to cells treated with NCS alone (n=3).

(I) Representative image of Beta gal staining of control and NCS-treated MCF7 cells in the presence of the MAPK inhibitor U0126, a single or multiple pulses of EGF and HRG, 4 days after treatment (related to Fig 2F)

(J) Quantification of number of MCF7 cells moving past G2 checkpoint and into mitosis when treated with NCS and EGF in the presence of Nutlin shows a stronger checkpoint arrest as compared to cells treated with NCS and NCS along with EGF (n=3).

(K) Contrary to transient stimulation, the sustained activation of MAPK signalling achieved with CRY2-cRaf increases the number of cells entering mitosis after DNA damage (NCS 200 ng/ml).
Figure S5. Sustained MAPK signalling attenuate p53 response and cell cycle arrest. Related to Figures 4.

(A) Representative Western blot showing asynchronous MCF-7 cells treated with NCS in the absence or presence of EGF (130ng/ml, n=2).
(B) Quantification of p53 expression as seen in panel A.
(C) Representative Western blot showing MCF-7 cells synchronised by means of double thymidine block and released into fresh medium for 6 hrs before treatment with NCS or NCS and HRG.
(D) Quantification of p53 expression levels as seen in panel C showing that HRG can attenuate the p53 response to DNA damage (n=3).
(E) Analysis of p53 expression levels in cells treated with HRG and DNA damage in the presence and absence of U0126 shows that p53 levels can be rescued in the presence of U0126.
(F) Representative western blot showing MCF-7 cells treated with HRG and DNA damage in the absence/presence of U0126 (n=2).

(G) Contrary to HRG, an EGF pulse is unable to induce PLK1 expression in the presence of DNA damage as shown by a representative Western blot depicting PLK1 expression in MCF-7 cells treated with NCS (200 ng/ml) and EGF (130 ng/ml) (n=2).

(H) Representative western blot showing MCF-7 cells synchronised by a double thymidine block and subsequently released into fresh medium for 6 hours before addition of Nocodazole. At the same time, cells were treated with NCS alone, or in the presence of HRG or HRG+U0126. After 6 hr of additional incubations, cells were lysed and probed for CDC25C T48 phosphorylation and total CDC25C levels (n=3) showing that HRG can increase CDC25C phosphorylation in the presence of DNA damage in a MAPK-dependent manner.
Figure S6. Sustained MAPK signalling attenuate p53 response and cell cycle arrest in RPE-1 cells. Related to Figure 4.

(A) Representative Western blot showing RPE-1 cells synchronised by means of double thymidine block and released into fresh medium for 6 hrs before treatment with NCS or NCS and HRG.

(B) Quantification of PLK1 expression levels as seen in panel A showing that HRG can increase the PLK1 even in presence of DNA damage (n=2). Analysis of p53 expression levels in cells treated with HRG and DNA damage in the shows that HRG can decrease the levels of p53.

(C) Representative Western blot showing that CDC25C phosphorylation at T48 in synchronised RPE-1 cells is decreased in response to DNA damage and is restored by HRG (n=2).
| dataset          | p value | test       |
|------------------|---------|------------|
| Fig. S3b – FOS   | 0.0085  | ANOVA      |
| Fig. S3b – EGR1  | 0.010   | ANOVA      |
| Fig. S3b – CTGF  | 0.0051  | ANOVA      |
| Fig. 1b          | <0.0001 | ANOVA      |
| Fig. 1b          | 0.0059  | ANOVA      |
| Fig. 2e          | 0.0074  | t test     |
| Fig. 2f          | <0.0001 | ANOVA      |
| Fig. 2g          | <0.0001 | ANOVA      |
| Fig. 2j          | <0.0001 | ANOVA      |
| Fig. 3e          | <0.0001 | ANOVA      |
| Fig. S2c         | <0.0001 | ANOVA      |
| Fig. S2e         | <0.0001 | ANOVA      |
| Fig. S5j         | <0.0001 | ANOVA      |
| Fig. S5k         | <0.0001 | ANOVA      |

**Supplementary Table.** Related to Fig. 1, 2, 3, S2, S4. Exact p values (unless <0.0001) and statistical tests. ANOVA: one-way ANOVA with Newman-Keuls multiple comparison test; t-test: two tailed paired t-test.